Navamedic ASA acquires Vitaflo Scandinavia AB and initiates a new strategic phase.

The acquisition of Vitaflo is the first step towards the creation of an international speciality pharmaceutical company, where Navamedic will provide valuable qualifications registration and approval processes and an international network within distribution/marketing. The acquisition does not change Navamedic's ambitions in the glucosamine market, where the focus on Glucomed/Flexove will continue with full intensity through existing distributions agreements.
Please se attachment for further information.

A presentation of the acquisition will be held in connection to with the Q2-presentation held today at 11.00 at Vika Atrium.

For further information, please contact:
Øyvind W. Brekke, CEO Navamedic ASA
E-mail: oyvind [dot] brekke [at] navamedic [dot] com
Office: +47 67 11 25 40
Mobile: +47 91 19 81 64

Bernt-Olav Røttingsnes, CFO/IRO Navamedic ASA
E-mail: bor [at] navamedic [dot] com
Office: +47 67 11 25 44
Mobile: +47 91 34 70 21